摘要
卡博替尼是一种小分子、多靶点的酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI),其相较于其他单靶点TKIs具有优势。FDA已批准卡博替尼用于治疗晚期肾细胞癌和转移性甲状腺髓样癌,且越来越多的临床研究提示该药在抗肿瘤治疗中具有潜力。本文主要介绍卡博替尼用于治疗肾细胞癌、甲状腺癌、前列腺癌、肝细胞癌和肺癌的作用机制与临床研究数据,以期为我国的临床实践提供参考。
Cabozantinib is a small-molecule,multitargeted tyrosine kinase inhibitor(TKI)that may confer an advantage over other TKIs that target a single receptor.It has been approved by the FDA for the treatment of both advanced renal cell carcinoma and progressive metastatic medullary thyroid cancer,and more and more clinical data show the great potential of the drug in antitumor therapy.This article mainly introduces the mechanism and clinical trial data of cabotinib in the treatment of renal cell carcinoma,thyroid carcinoma,prostate cancer,hepatocellular carcinoma and lung cancer,in order to provide reference for the clinical practice in China.
作者
汪龙
张莉
汪娟
葛朝亮
WANG Long;ZHANG Li;WANG Juan;GE Chao-liang(Department of Pharmacy,the Third People's Hospital of Bengbu,Bengbu 233099,China;Department of Pharmacy,the Second Affiliated Hospital of Bengbu Medical College,Bengbu 233040,China;Department of Emergency,East City Hospital of Shanghai Yangpu District,Shanghai 200438,China;Department of Pharmacy,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2019年第20期2486-2491,共6页
Chinese Journal of New Drugs
关键词
卡博替尼
酪氨酸激酶抑制剂
肾细胞癌
甲状腺癌
前列腺癌
cabozantinib
tyrosine kinase inhibitor
renal cell cancer
thyroid cancer
prostate cancer
